At YNIOS PHARMA, our lead compound TA64 is built on a novel therapeutic approach targeting the core pathophysiological mechanisms that drive critical illness, starting with septic shock. These mechanisms — including dysregulated inflammation, endothelial dysfunction, microvascular failure, immune exhaustion, and intense physiological stress — are not exclusive to one condition but are shared across a wide range of life-threatening ICU syndromes. TA64 is engineered to intervene upstream in this cascade, offering a unique opportunity to modulate the vicious cycle of pro-inflammation and organ failure at its root.

TA64 is designed to restore-maintain the natural capacity of cells to regulate innate immune responses appropriately in the face of severe inflammatory insults. Unlike conventional anti-inflammatory agents that broadly suppress immune activity, TA64 supports a targeted, proportional immune response — strong enough to repress the trigger but controlled enough to avoid collateral tissue damage. This immunomodulatory balance is critical in preventing progression from systemic inflammation to irreversible organ dysfunction.

Most importantly, TA64’s mechanism preserves and protects healthy cell integrity under stress. By stabilizing cellular environments and promoting endothelial resilience, the compound helps maintain vascular barrier function and microcirculatory flow — both essential to preventing hypoxia and multi-organ failure. In doing so, TA64 actively supports tissue homeostasis and the restoration of organ function, rather than merely delaying deterioration.